Pei Yuqing, Li Kexin, Lou Xiaoying, Wu Yue, Dong Xin, Wang Wenpeng, Li Ning, Zhang Donghong, Cui Wei
State Key Laboratory of Molecular Oncology, Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China.
Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, P.R. China.
Oncol Rep. 2023 May;49(5). doi: 10.3892/or.2023.8533. Epub 2023 Mar 24.
Following the publication of the above article, a concerned reader drew to the authors' attention that the data shown for the 'CAOV3/NC mimics' experiment in Fig. 2D on p. 443 appeared to be the same as that shown for the 'TUG1‑sh+miR‑1299 inhibitors' experiment in Fig. 4H on p. 444. The authors have examined their original data, and realize that the same data was inadvertently included in the two figures. Consequently, the corrected version of Fig. 2, featuring the correct data for the 'CAOV3/NC mimics' experiment in Fig. 2D, is shown opposite. The overall conclusions of this study were not affected by this error. All the authors agree to the publication of this corrigendum, and are grateful to the Editor of for allowing them the opportunity to publish this; furthermore, they apologize to the readership for any inconvenience caused. [Oncology Reports 44: 438-448, 2020; DOI: 10.3892/or.2020.7623].
上述文章发表后，一位关注此事的读者提请作者注意，第443页图2D中“CAOV3/NC模拟物”实验所示的数据似乎与第444页图4H中“TUG1-sh+miR-1299抑制剂”实验所示的数据相同。作者检查了原始数据，意识到相同的数据被无意中包含在这两个图中。因此，图2的更正版本如下所示，其中图2D展示了“CAOV3/NC模拟物”实验的正确数据。本研究的总体结论未受此错误影响。所有作者均同意发表本勘误，并感谢《肿瘤学报告》编辑给予他们发表此勘误的机会；此外，他们就由此造成的不便向读者致歉。[《肿瘤学报告》44: 438 - 448, 2020; DOI: 10.3892/or.2020.7623]
